Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
Ganaxolone IV Program Aimed at Status Epilepticus Target Indication...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
Conference Call Today at 8:00 a.m. ET...
View HTML
Toggle Summary Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference
RADNOR, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will be participating in the Bank of America Merrill...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
RADNOR, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for...
View HTML
Toggle Summary Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
Data Presented at the American Academy of Neurology Annual Meeting Phase 1 Clinical Program On-Track to Initiate in 1H 2016 RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) --   Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative...
View HTML
Toggle Summary Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
RADNOR, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML
Toggle Summary Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
Selected for Dual Oral and Poster Presentations on Ganaxolone IV in Diazepam-Resistant Model of Status Epilepticus...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
RADNOR, Pa., March 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference
RADNOR, Pa., March 01, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M....
View HTML
Toggle Summary Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
RADNOR, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will participate in the Canaccord Genuity 2016 Rare...
View HTML